Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Sorfenib works by slowing the spread of cancer cells. It has been used in other studies for
patients with AML with the FLT3-ITD mutation and information from these studies suggests that
sorafenib may help to control leukemia. The purpose of this study is to find the highest dose
of sorafenib for maintenance therapy that can be safely used in participants with AML who
have undergone allogeneic stem cell transplant.